Dr. Kenika explaining Wegovy semaglutide titration plan to patient at TRT Bangkok

Authentic Novo Nordisk · Obesity Indication

Wegovy Thailand

Authentic Wegovy from Novo Nordisk — FDA-approved Semaglutide for chronic weight management. Cold-chain delivery across Thailand. International patients travel to our Pattaya clinic; Singapore monthly courier.

US FDA-approved · June 2021 · Chronic Weight Management
14.9% body-weight reduction (STEP-1, 2.4 mg, 68 weeks)
Verifiable batch numbers · Pre-filled pen · 0.25 – 2.4 mg / week

Request consultation → Get Started ↓

Dr. Kenika presenting Wegovy treatment options at TRT Bangkok

Dr. Kenika, Medical Director

Medical Council of Thailand · Personal supervision

Authentic

Novo Nordisk Pen

Doctor-Led

Dr. Kenika · MD

Trusted

Verified 5.0

Cold-Chain

Pharmacy-Grade Delivery

Body-weight reduction · STEP-1 trial

−14.9%

Mean body-weight reduction in the STEP-1 trial at 68 weeks on Wegovy 2.4 mg.

Wilding et al., NEJM 2021 · n=1,961 non-diabetic adults

What that means for you

Your weight

That's −12.7 kg — you'd weigh 72.3 kg.

Based on the 14.9% trial-mean. Individual outcomes vary.

Dr. Kenika explaining personalized GLP-1 weight-loss treatment plan on tablet during consultation at TRT Bangkok

Dr. Kenika explaining Wegovy dosing protocol

Authentic Novo Nordisk Wegovy consultation at TRT Bangkok

Licensed medical facility · Real photos · Dr. Kenika

FDA Indication

Wegovy is the Obesity-Indication Brand

Wegovy is FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) plus weight-related comorbidities such as hypertension, dyslipidemia, or sleep apnea. The molecule — Semaglutide — is the same one marketed under the Ozempic brand for Type 2 diabetes, but Wegovy uses a higher dose range (up to 2.4 mg vs Ozempic's 2 mg).

How Wegovy Works

Semaglutide Molecule

GLP-1 receptor agonist activating appetite-regulation pathways in the brain. Slows gastric emptying, reduces hunger, suppresses food cravings. Single-pathway mechanism (vs. Tirzepatide's dual GIP/GLP-1).

Read more about the molecule on our Semaglutide Thailand page.

Wegovy vs Ozempic

Same Molecule, Different Indication

Wegovy: Obesity indication (June 2021). Ozempic: Type 2 diabetes. Both contain Semaglutide manufactured by Novo Nordisk. Dr. Kenika selects based on clinical situation.

See Ozempic Thailand.

Program Investment

Authentic Wegovy Program

Doctor-led · Authentic Novo Nordisk · Cold-Chain

from 1,990 ฿ per shot

↑ Take-home pens available from 14,990 ฿/month

Every program includes

Doctor consultation

Individualized dose plan

Ongoing monitoring

Cold-chain delivery

Wegovy (semaglutide) is FDA-approved for chronic weight management. Once-weekly GLP-1 receptor agonist with the largest body of weight-loss clinical evidence to date.

Discuss your Wegovy program on WhatsApp →

See full take-home pen options (14,990 ฿ — 29,990 ฿)

0.25 mg pen

14,990 ฿

Initiation · weeks 1-4

0.50 mg pen

14,990 ฿

Titration · weeks 5-8

1.0 mg pen

16,990 ฿

Therapeutic · weeks 9-12

1.7 mg pen

23,590 ฿

Up-titration · weeks 13-16

2.4 mg pen

29,990 ฿

Maximum · weeks 17+

Per-shot pricing at higher doses confirmed during your consultation. Final program pricing depends on your dose plan and treatment duration. Thai pharmacy advertising regulations preclude binding online prices — your exact figure is shared in private medical review.

Your Personalized Trajectory

See your expected trajectory on Wegovy.

Trajectory based on the STEP-1 clinical-trial mean. Your individualized program is confirmed in consultation — this is an evidence-based estimate, not a guarantee.

Current weight

Goal weight

Treatment

Wegovy

Your trajectory · based on STEP-1 mean (Wegovy)

Weeks to goal

—

Projected loss

—

Monthly investment

from 1,990 ฿/shot

Book your personalized program review →

Estimator uses peer-reviewed clinical-trial mean data. Individual outcomes vary based on adherence, baseline BMI, comorbidities, and lifestyle factors. Final program plan determined in private medical consultation.^[ref]

Novo Nordisk Titration

Standard Wegovy Dose-Escalation

Wegovy follows the Novo Nordisk prescribing-information titration. Incremental dose increases minimize GI side effects.

View titration schedule

Weeks 1-4

0.25 mg weekly

Adaptation phase. Sub-therapeutic.

Weeks 5-8

0.5 mg weekly

First therapeutic step.

Weeks 9-12

1 mg weekly

Up-titration if tolerated.

Weeks 13-16

1.7 mg weekly

Intermediate dose.

Weeks 17+

2.4 mg weekly

Wegovy maximum — STEP-1 efficacy reference^[1].

Source: Novo Nordisk Wegovy prescribing information. Adapted individually by Dr. Kenika.

How It Works

A simple, medically supervised path to your Wegovy program.

Discovery Call

15-minute WhatsApp with our clinic team. Share your goals, history, and questions. No commitment.

Medical Evaluation

Dr. Kenika reviews your history. Labs ordered if needed. Treatment plan decided based on your specific clinical picture.

Start Treatment

First dose at clinic or cold-chain delivery to your address. Titration plan + side-effect support from day one.

Track & Adjust

Weekly check-ins during titration. Dose adjusted to your response. Sustainable maintenance plan together.

Book your free discovery call →

Why TRT Bangkok

Three foundations of our weight-loss program.

DOCTOR-LED CARE

Every Wegovy patient is personally supervised by Dr. Kenika — medical history review, HbA1c monitoring where relevant, dose decisions, titration adjustments. No intake-form-only approval.

100%

MANUFACTURER-DIRECT

Authentic Wegovy from Novo Nordisk via cold-chain pharmacy distribution. Batch numbers and expiry dates intact. No compounded substitutes, no grey-market sourcing.

Novo Nordisk

THREE ACCESS MODES

In-clinic in Pattaya, concierge nurse to your hotel in Bangkok, or online consultation with cold-chain delivery in Phuket and beyond.

3 Ways

Your Doctor

Meet Your Medical Director

Dr. Kenika Norrachetdecha, MD

Medical Director · TRT Bangkok

Hormone MedicineBrain HealthMetabolic OptimisationWeight Loss

Dr. Kenika Norrachetdecha, MD, leads TRT Bangkok's clinical practice. She specialises in hormone optimisation, regenerative medicine, and metabolic health, with advanced training under Dr. Mark Gordon (USA). Every Wegovy patient is personally supervised by Dr. Kenika.

3.000+

Patients Treated

500+

IV Treatments

3.000+

TRT Treatments

1.000+

GLP-1 Treatments

International Training

Advanced training under Dr. Mark Gordon (USA) — featured on The Joe Rogan Experience.

With Dr. Mark Gordon (USA)

HEAT Conference

Thai Medical License #72509 · Council Member #71253 — Verify ↗

Frequently Asked

Common Questions About Wegovy

Is this authentic Wegovy from Novo Nordisk?

Yes. Wegovy is manufactured by Novo Nordisk A/S. Each pen at TRT Bangkok ships through cold-chain pharmaceutical distribution with batch numbers, manufacturer markings, and expiry dates intact. You can verify before your first injection.

Wegovy vs Ozempic — what is the difference?

Same active molecule (Semaglutide). Wegovy: chronic weight management, doses 0.25-2.4 mg weekly. Ozempic: Type 2 diabetes, doses 0.25-2 mg weekly. Pharmacologically identical molecule; different label and maximum dose. See Ozempic Thailand.

How much weight will I lose on Wegovy?

In STEP-1, adults on Wegovy 2.4 mg weekly lost an average 14.9% of body weight over 68 weeks. Lower doses produce proportionally less weight loss. Individual results depend on starting BMI, adherence, and lifestyle support.

What are the side effects of Wegovy?

Most common: nausea, decreased appetite, mild GI discomfort during the first 4-8 weeks of titration. These typically diminish as your body adapts. Rare considerations: pancreatitis history and family history of medullary thyroid carcinoma — reviewed with Dr. Kenika.

How do I store Wegovy at home?

Refrigerator 2-8°C. Once in use, room temperature (below 30°C) for up to 56 days. Do not freeze, avoid direct sunlight. In Thai climate, never leave the pen on a car dashboard or balcony.

How does Wegovy pricing compare to the US, UK, Australia?

Thailand pricing for authentic Novo Nordisk Wegovy is meaningfully below US cash-pay rates (NovoCare lists Wegovy from approximately USD 499/month at certain doses) and competitive with UK and Australian markets. Exact figure during consultation.

Can I switch from Wegovy to Tirzepatide (Zepbound)?

Yes — Tirzepatide (Zepbound) adds GIP-receptor activity to the GLP-1 mechanism Wegovy uses, typically producing stronger weight loss. Most patients begin Tirzepatide at 2.5 mg even when transitioning from a maintenance Wegovy dose. See Zepbound Thailand.

Patient Reviews

What patients say

5.0 / 5

15 verified Google Reviews

Real reviews from real patients on Google Business Profile. Currently 5.0 ★ from 15 verified reviews — and growing.

[Robert: paste actual Google Review quote — topic-filtered for this page]

[Robert: First name + initial]

[Robert: month year]

[Robert: paste actual Google Review quote — topic-filtered for this page]

[Robert: First name + initial]

[Robert: month year]

[Robert: paste actual Google Review quote — topic-filtered for this page]

[Robert: First name + initial]

[Robert: month year]

Read all reviews on Google Business Profile →

Ready to start Wegovy?

Request a consultation. Our clinic team responds within minutes on WhatsApp.

Request consultation

Medically reviewed by Dr. Kenika, Medical Director

Member, Medical Council of Thailand · Endocrinology & Metabolic Medicine

This page is reviewed for medical accuracy. Content is informational and does not substitute for individualized medical advice.

Sources

Peer-reviewed primary sources, FDA prescribing information, manufacturer documentation.

View all 5 sources

Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183. View on NEJM ↗
U.S. FDA. Wegovy (semaglutide) injection prescribing information. Initial Approval: 2021. FDA label (PDF) ↗
U.S. FDA. Ozempic (semaglutide) injection prescribing information. Initial Approval: 2017. FDA label (PDF) ↗
Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834-1844. View on NEJM ↗
American Diabetes Association. Standards of Care in Diabetes 2024. Diabetes Care. 2024;47(Suppl 1):S158-S178. View ↗

Additional clinical questions discussed during your private consultation with Dr. Kenika.

Wirkstoff-Anchor

Semaglutide Thailand

Active molecule reference

Cluster overview with quiz

Cross-Wirkstoff

Tirzepatide Thailand